Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2019 07:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members

Long Beach, CA, April 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
April 08, 2019 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

LONG BEACH, CA, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
April 01, 2019 07:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
March 25, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments

Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
March 18, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing

Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
March 13, 2019 07:36 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience to Present at 31st Annual ROTH Conference

Long Beach, CA, March 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
March 12, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues

Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
March 04, 2019 07:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog

Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
February 14, 2019 07:00 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma

Long Beach, CA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
February 07, 2019 08:30 ET | Source: Nemus Bioscience, Inc.

Nemus Bioscience to Present at BIO CEO & Investor Conference

LONG BEACH, CA, Feb. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right